Literature DB >> 15099287

Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.

C E Hagemeyer1, I Tomic, U Weirich, J Graeber, T Nordt, M S Runge, C Bode, K Peter.   

Abstract

BACKGROUND: Targeting of plasminogen activators to the fibrin component of a thrombus by antibodies directed against human fibrin can enhance their thrombolytic potency and clot specificity.
OBJECTIVES: To overcome the disadvantages of chemical conjugation, we investigated whether the recombinant fusion of a single-chain antibody and a plasminogen activator results in an active bifunctional molecule that might be useful as a therapeutic agent.
METHODS: The cDNA of low-molecular-weight single-chain urokinase-type plasminogen activator, comprising amino acids Leu144-Leu411 (scuPA(LMW)), was cloned from human endothelial cells and fused to a single-chain antibody specific for the 7 N-terminal amino acids (beta(15-22)) in the beta-chain of human fibrin (scFv(59D8)). The fusion protein was purified using affinity chromatography with the beta(15-22)-peptide of human fibrin.
RESULTS: Purified scFv(59D8)-scuPA(LMW) migrated as a 60-kDa band, which is consistent with a molecule composed of one scFv(59D8) and one scuPA(LMW) moiety. Both functions of the fusion molecule, fibrin-specific binding and plasminogen activation, were fully preserved. In human plasma clots, thrombolysis by scFv(59D8)-scuPA(LMW) is significantly faster and more potent compared with the clinically used urokinase.
CONCLUSIONS: ScFv(59D8)-scuPA(LMW) constitutes a new recombinant chimeric plasminogen activator with a significantly enhanced thrombolytic potency and relative fibrin selectivity, that can be produced with modern methods at low cost, large quantities and reproducible activity in Escherichia coli.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099287     DOI: 10.1111/j.1538-7836.2004.00697.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Kristina Danielyan; Juan-Carlos Murciano; Kumkum Ganguly; Tatiana Krasik; Ronald P Taylor; Steven Pincus; Steven Jones; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2006-05-30       Impact factor: 22.113

2.  Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.

Authors:  Bi-Sen Ding; Claudia Gottstein; Andrea Grunow; Alice Kuo; Kumkum Ganguly; Steven M Albelda; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

3.  Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?

Authors:  Jan David Hohmann; Xiaowei Wang; Stefanie Krajewski; Carly Selan; Carolyn A Haller; Andreas Straub; Elliot L Chaikof; Harshal H Nandurkar; Christoph E Hagemeyer; Karlheinz Peter
Journal:  Blood       Date:  2013-02-04       Impact factor: 22.113

4.  Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature.

Authors:  Bi-Sen Ding; Nankang Hong; Juan-Carlos Murciano; Kumkum Ganguly; Claudia Gottstein; Melpo Christofidou-Solomidou; Steven M Albelda; Aron B Fisher; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2007-11-28       Impact factor: 22.113

5.  Endogenously generated plasmin at the vascular wall injury site amplifies lysine binding site-dependent plasminogen accumulation in microthrombi.

Authors:  Tomasz Brzoska; Aki Tanaka-Murakami; Yuko Suzuki; Hideto Sano; Naohiro Kanayama; Tetsumei Urano
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

6.  Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa.

Authors:  Thomas Bonnard; Zachary Tennant; Be'Eri Niego; Ruchi Kanojia; Karen Alt; Shweta Jagdale; Lok Soon Law; Sheena Rigby; Robert Lindsay Medcalf; Karlheinz Peter; Christoph Eugen Hagemeyer
Journal:  J Am Heart Assoc       Date:  2017-02-03       Impact factor: 5.501

7.  Studies on polyethylene glycol-monoclonal antibody conjugates for fabrication of nanoparticles for biomedical applications.

Authors:  Funmilola Fisusi; Nailah Brandy; Jingbo Wu; Emmanuel O Akala
Journal:  J Nanosci Nanomed       Date:  2020-02-03

8.  A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase.

Authors:  Shingo Hanaoka; Shinji Saijou; Yasuhiro Matsumura
Journal:  Thromb Haemost       Date:  2021-06-15       Impact factor: 6.681

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.